Young-Seol Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Young-Seol Kim has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jung-Eun Yim
Department of Food and Nutrition, Changwon National University, Changwon 51140, Republic of Korea
4 shared publications - Ha-Neul Choi
Department of Food and Nutrition, Changwon National University, Changwon 51140, Korea
2 shared publications - Hina Akbar
Interdisciplinary Program in Senior Human Ecology, Changwon National University, Changwon 51140, Korea
1 shared publication In Kook Park
Department of Applied Biology, College of Life Resource Science, Dongguk University, Seoul, Korea
1 shared publicationIn Myung Yang
Division of Endocrinology & Metabolism, Department of Internal Medicine, Endocrine Research Institute, Kyung Hee University School of Medicine, Seoul, Korea
1 shared publication- Jeong-Taek Woo
Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul 02447, Korea
1 shared publication
Latest Publications
- 29 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 6084-6087
Comparative efficacy and safety of Evogliptin in type 2 diabetes patients above and below 65 years
- 29 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (10) , 6084-6087
Comparative efficacy and safety of Evogliptin in type 2 diabetes patients above and below 65 years
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Nutrition and Health
- Vol. 57 (3) , 282-291
Impact of dietary fiber intake on non-alcoholic fatty liver disease risk in Korean patients with obesity and type 2 diabetes mellitus
Park JS, et al. J Nutr Health. 2024 Jun;57(3):282-291. https://doi.org/10.4163/jnh.2024.57.3.282
- 1 January 2024
- Published by XMLink in Journal of Nutrition and Health
- Vol. 57 (3) , 282-291
Open AccessImpact of dietary fiber intake on non-alcoholic fatty liver disease risk in Korean patients with obesity and type 2 diabetes mellitus
Park JS, et al. J Nutr Health. 2024 Jun;57(3):282-291. https://doi.org/10.4163/jnh.2024.57.3.282
- Open Access
- 1 January 2024
- Published by XMLink in Nutrition Research and Practice
- Vol. 18 (1) , 78-87
Association of daily carbohydrate intake with intermuscular adipose tissue in Korean individuals with obesity: a cross-sectional study
Choi HN, et al. Nutr Res Pract. 2024 Feb;18(1):78-87. https://doi.org/10.4162/nrp.2024.18.1.78
- 1 January 2024
- Published by XMLink in Nutrition Research and Practice
- Vol. 18 (1) , 78-87
Open AccessAssociation of daily carbohydrate intake with intermuscular adipose tissue in Korean individuals with obesity: a cross-sectional study
Choi HN, et al. Nutr Res Pract. 2024 Feb;18(1):78-87. https://doi.org/10.4162/nrp.2024.18.1.78
- Open Access
- 1 January 2020
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 9 (3) , 205-212
Independent Association of Phase Angle with Fasting Blood Glucose and Hemoglobin A1c in Korean Type 2 Diabetes Patients
Choi HN, et al. Clin Nutr Res. 2020 Jul;9(3):205-212. https://doi.org/10.7762/cnr.2020.9.3.205
- 1 January 2020
- Published by Korean Society of Clinical Nutrition in Clinical Nutrition Research
- Vol. 9 (3) , 205-212
Open AccessIndependent Association of Phase Angle with Fasting Blood Glucose and Hemoglobin A1c in Korean Type 2 Diabetes Patients
Choi HN, et al. Clin Nutr Res. 2020 Jul;9(3):205-212. https://doi.org/10.7762/cnr.2020.9.3.205
- 31 July 2018
- Published by Korean Institute of Information Technology in The Journal of Korean Institute of Information Technology
- Vol. 16 (7) , 67-75
Design and Analysis of a Strong Designated Verifier Blind Signature Scheme
- 31 July 2018
- Published by Korean Institute of Information Technology in The Journal of Korean Institute of Information Technology
- Vol. 16 (7) , 67-75
Design and Analysis of a Strong Designated Verifier Blind Signature Scheme
- Top Cited PapersOpen Access
- 1 January 2018
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 42 (3) , 188-195
The Role of Advanced Glycation End Products in Diabetic Vascular Complications
Rhee SY, et al. Diabetes Metab J. 2018 Jan;42:e17. https://doi.org/10.4093/dmj.2017.0105
- 1 January 2018
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 42 (3) , 188-195
Top Cited PapersOpen AccessThe Role of Advanced Glycation End Products in Diabetic Vascular Complications
Rhee SY, et al. Diabetes Metab J. 2018 Jan;42:e17. https://doi.org/10.4093/dmj.2017.0105
- Open Access
- 30 July 1999
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 14 (2) , 34-40
Effect of Cilostazol on the Neuropathies of Streptozotocin - induced Diabetic Rats
This study examined the effect of cilostazol, a potent phosphodiesterase inhibitor, on the progression of neuropathies associated with streptozotocin-induced diabetes mellitus in Sprague-Dawley rats. Eight weeks after streptozotocin treatment, a pelleted diet containing 0.03% cilostazol (15 mg/kg body weight) was given for four weeks. Body weight, blood glucose level, motor nerve conduction velocity (MNCV), myelinated fiber density and size distribution of sciatic nerves were compared between age-matched normal rats (Group 1), control diabetic rats (Group 2) and cilostazol-treated diabetic rats (Group 3). Body weight was significantly reduced and blood glucose level was significantly increased in diabetic rats (Group 2 and 3) compared to normal rats. MNCV and cAMP content of sciatic nerves were significantly reduced in diabetic rats 12 weeks after streptozotocin treatment. Myelinated fiber size and density were also significantly reduced, and thickening of the capillary walls and duplication of the basement membranes of the endoneural vessels were observed in the diabetic rats. Whereas both body weight and blood glucose level of Group 3 did not differ significantly from those of Group 2, cilostazol treatment significantly increased MNCV and cAMP content of sciatic nerves in Group 3 but not to the levels observed in Group 1. MNCV positively correlated with cAMP content of sciatic nerves (r = 0.86; p < 0.001). Cilostazol treatment not only restored myelinated fiber density and size distribution but reversed some of the vascular abnormalities. These findings suggest that a reduced cAMP content in motor nerves may be involved in the development of diabetic neuropathy, and that cilostazol may prevent the progression of diabetic neuropathy by restoring functional impairment and morphological changes of peripheral nerves.
- 30 July 1999
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 14 (2) , 34-40
Open AccessEffect of Cilostazol on the Neuropathies of Streptozotocin - induced Diabetic Rats
This study examined the effect of cilostazol, a potent phosphodiesterase inhibitor, on the progression of neuropathies associated with streptozotocin-induced diabetes mellitus in Sprague-Dawley rats. Eight weeks after streptozotocin treatment, a pelleted diet containing 0.03% cilostazol (15 mg/kg body weight) was given for four weeks. Body weight, blood glucose level, motor nerve conduction velocity (MNCV), myelinated fiber density and size distribution of sciatic nerves were compared between age-matched normal rats (Group 1), control diabetic rats (Group 2) and cilostazol-treated diabetic rats (Group 3). Body weight was significantly reduced and blood glucose level was significantly increased in diabetic rats (Group 2 and 3) compared to normal rats. MNCV and cAMP content of sciatic nerves were significantly reduced in diabetic rats 12 weeks after streptozotocin treatment. Myelinated fiber size and density were also significantly reduced, and thickening of the capillary walls and duplication of the basement membranes of the endoneural vessels were observed in the diabetic rats. Whereas both body weight and blood glucose level of Group 3 did not differ significantly from those of Group 2, cilostazol treatment significantly increased MNCV and cAMP content of sciatic nerves in Group 3 but not to the levels observed in Group 1. MNCV positively correlated with cAMP content of sciatic nerves (r = 0.86; p < 0.001). Cilostazol treatment not only restored myelinated fiber density and size distribution but reversed some of the vascular abnormalities. These findings suggest that a reduced cAMP content in motor nerves may be involved in the development of diabetic neuropathy, and that cilostazol may prevent the progression of diabetic neuropathy by restoring functional impairment and morphological changes of peripheral nerves.